Please login to the form below

Not currently logged in
Email:
Password:

Eisai/ UCL partnership grows

Eisai is to extend its partnership with University College London, a UK-based university with which the company has been collaborating with for more than 20 years

Eisai is to extend its partnership with University College London (UCL), a UK-based university with which the company has been collaborating with for more than 20 years.

The new phase will see the Eisai and UCL engage in joint research in neurodegenerative disease including biomarker research into neuroinflammation, neurovascular/mitochondria and proteostasis.

During the course of their partnership which began in 1990, Eisai and UCL established an Eisai research facility on the UCL campus and have forged strong co-operative ties through research activities that included the exchange of personnel.

Additionally Eisai said it plans to submit marketing authorisation applications to the regulatory authorities in the US and Europe for perampanel, a first-in-class, highly selective, non-competitive AMPA-type glutamate receptor antagonist that was created through collaborative with UCL research, to complement its marketed products which include Zonegran (zonisamide), Inovelon (rufinamide) and Zebinix (eslicarbazepine acetate).

26th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics